Joshua Levy
Clinical Director · Clinical Center at the National Institutes of Health
Credentials: · · · · · · ·
History
- Present
- Present
Division of Head and Neck Surgery · Vanderbilt University Medical Center
- 2018–2019
- 2017–2018
- 2006–2010
Research
International consensus statement on allergy and rhinology: rhinosinusitis 2021
Review · International Forum of Allergy & Rhinology · 2021 · 768 citations
International consensus statement on allergy and rhinology: Allergic rhinitis - 2023
Review · International Forum of Allergy & Rhinology · 2023 · 401 citations
International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
International Forum of Allergy & Rhinology · 2018 · 399 citations

27 papers
- JD
19 papers

16 papers · 5 as a fellow
- TS
14 papers
- WL
12 papers

10 papers · 3 as a fellow

9 papers

7 papers
Grants
- 2021–2023
Endogenous Cannabinoids in Inflammatory Airway Disease
National Center for Advancing Translational Sciences · R03
Contact PI · $156.5K · Emory University
NIDCD Core for Clinical Research and Care
National Institute on Deafness and Other Communication Disorders · ZID
Contact PI · $9.9M · National Institute on Deafness and Other Communication Disorders
Sinonasal and Olfaction Program
National Institute on Deafness and Other Communication Disorders · ZIA
Contact PI · $2.5M · National Institute on Deafness and Other Communication Disorders
Space Activation - Clinical Director - National Taste & Smell
National Institute on Deafness and Other Communication Disorders · ZII
Contact PI · $1.6M · National Institute on Deafness and Other Communication Disorders
Clinical trials
- 2026–2029
Principal investigator · Enrolling by invitation
National Institute on Deafness and Other Communication Disorders (NIDCD)
- 2024
Principal investigator · Withdrawn · Phase 3
National Institute on Deafness and Other Communication Disorders (NIDCD)
- 2024–2033
NIDCD Otolaryngology Clinical Protocol Biospecimen Bank
Principal investigator · Recruiting
National Institute on Deafness and Other Communication Disorders (NIDCD)
- 2023–2024
Add-on Dupilumab for AFRS as Postoperative Therapy (ADAPT)
Principal investigator · Terminated · Phase 3
Emory University

